MedTrace Logo

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

NCT03104478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 219

Last updated 2021-12-07

No results posted yet for this study

Summary

The trial will enroll 194 previously untreated DLBCL patients over 20 months, with the objective to send to the local investigator an extensive molecular tumor characterization by D38 in at least 80% of enrolled patients.

The feasibility and efficiency will be demonstrated by deploying and operating a nation-wide network of dedicated multidisciplinary platforms.

Conditions

Interventions

PROCEDURE

Biological samples collection

In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.

Sponsors & Collaborators

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Fabrice Jardin, Pr · Lymphoma Study Association

  • Christiane Copie, Pr · Lymphoma Study Association

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-09
Primary Completion
2019-10-11
Completion
2021-09-04

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03104478 on ClinicalTrials.gov